Status:

COMPLETED

Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma

Lead Sponsor:

London School of Hygiene and Tropical Medicine

Collaborating Sponsors:

Federal Minstry of Health of Ethiopia

Oromia Regional Health Bureau, Ethiopia

Conditions:

Trachoma

Eligibility:

All Genders

3-65 years

Phase:

PHASE2

Brief Summary

Musca sorbens, a fly that feeds from ocular and nasal discharge on humans, is thought to be the vector of trachoma. We are developing methods of fly control that specifically target this species, in t...

Detailed Description

Introduction Trachoma Trachoma, a Neglected Tropical Disease (NTD), is the commonest infectious cause of blindness globally, affecting some of the world's poorest communities. Trachoma is caused by ...

Eligibility Criteria

Inclusion

  • Laboratory trial eligibility criteria
  • Participant is aged \> 18 years and \< 65 years and in good health
  • Participant has a good understanding of the procedures of the study and agrees to abide to these procedures
  • Participant is able to communicate well with the investigator, and attend the laboratory for all aspects of the laboratory studies
  • Participant has no known adverse reactions, or evidence at screening of adverse reactions, to the commercially available repellents DEET, PMD, IR3535, Picaridin or Permethrin, or to Vanilla
  • Participant has no known history of skin allergies or hypersensitivity to topical creams
  • Participant agrees to a pre-trial skin reactivity test for all the repellents that will be used in the trial
  • If in the event of the participant experiencing an adverse reaction to a repellent during the trial, the participant agrees to inform his/her general practitioner and seek appropriate treatment if necessary
  • Participant is willing to allow laboratory-reared Musca sorbens flies to land and crawl on their arm, during the modified arm-in-cage assay, for periods of up to ten minutes at a time
  • Participant agrees not to use any perfumed or scented product, including bathing products, for a 24-hour period before each laboratory session
  • Participant has signed informed consent
  • Participant is not a smoker, and will agree to refraining from smoking for the 12 hours before each laboratory trial
  • Field trial eligibility criteria
  • Participant lives in the designated study site
  • Participating households must be within a one-hour drive of Feya General Hospital
  • Participant considers themselves to be in good health, as does the parent or guardian
  • Participant is aged \> 3 years and \< 12 years
  • Participant has a good understanding of the procedures of the study and agrees to abide to these procedures
  • The parent or guardian of the participant has a good understanding of the procedures of the study and agrees to abide to these procedures
  • Participant is able to communicate well with the investigator or fieldworker who is conducting the study
  • Participant has no known adverse reactions to the commercially available repellents DEET, PMD, IR3535, Picaridin or Permethrin, or to Vanilla
  • Participant has no known history of skin allergies or hypersensitivity to topical creams
  • Participant agrees to a pre-trial skin reactivity test for all the repellents that will be used in the trial
  • If in the event of the participant experiencing an adverse reaction to a repellent during the trial, the participant can request medical advice from the Stronger-SAFE field team nurses if they wish
  • Participant is willing to sit still on a chair outside their house, for sequential periods of up to ten minutes, allowing wild fly contact and landing on the body and face, as much as possible without disturbing fly behaviour
  • Participant agrees not to use any perfumed or scented product, including bathing products, for a 24-hour period before each laboratory session
  • Able and willing to give fully informed assent
  • The parent or guardian has signed informed consent

Exclusion

    Key Trial Info

    Start Date :

    January 10 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 23 2019

    Estimated Enrollment :

    64 Patients enrolled

    Trial Details

    Trial ID

    NCT03813069

    Start Date

    January 10 2019

    End Date

    December 23 2019

    Last Update

    April 8 2020

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Fred Hollows Foundation

    Addis Ababa, Ethiopia

    2

    London School of Hygiene and Tropical Medicine

    London, United Kingdom, WC1E 7HT